Skip to main content
Erschienen in: Esophagus 1/2022

12.08.2021 | Original Article

Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan

verfasst von: Tomonori Nakanoko, Masaru Morita, Yuichiro Nakashima, Mitsuhiko Ota, Masahiko Ikebe, Manabu Yamamoto, Eisuke Booka, Hiroya Takeuchi, Yuko Kitagawa, Hisahiro Matsubara, Yuichiro Doki, Yasushi Toh

Erschienen in: Esophagus | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

No post-treatment follow-up methods have been established yet for patients with esophageal carcinoma who undergo radical esophagectomy (Surg) or who show complete response to definitive chemoradiotherapy (dCRT-CR). The purpose of this study was to investigate the current status of follow-up of the Surg and dCRT-CR patients in Japan, and understand the current reality and problems to establish an optimal follow-up method.

Methods

A questionnaire on the follow-up method adopted was sent by e-mail to 124 institutions approved by the Japan Esophageal Society as training institutions for board-certified esophageal surgeons; responses were received from 89 institutions. The data were compared with those obtained by a similar survey conducted in 2014.

Results

Follow-up methods markedly varied among institutions. Almost all institutions scheduled computed tomography and upper gastrointestinal endoscopy at least once a year up to postoperative year 5 for both the Surg and dCRT-CR groups. At least 70% of the institutions continued follow-up up to postoperative year 10, and this proportion had increased as compared to that reported from the 2014 survey. Only 25–30% of the institutions scheduled follow-up screening for metachronous head and neck cancer for both groups, and the health-related quality of life (HR-QOL) after the treatment were seldom assessed. These trends remained unchanged as compared to those reported from the 2014 survey.

Conclusions

The results suggest that the consensus of follow-up protocol could not be established. More attention is required for detection of metachronous cancers and assessment of the HR-QOL. Establishment of a consensus-based follow-up system and verification of its effectiveness are required.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat NCCN Guidelines Version 5. 2020, Esophageal and Esophagogastric Junction Cancers. 2020 NCCN Guidelines Version 5. 2020, Esophageal and Esophagogastric Junction Cancers. 2020
2.
Zurück zum Zitat Lordick F, Mariette C, Haustermans K, ESMO Guidelines Committee, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.CrossRef Lordick F, Mariette C, Haustermans K, ESMO Guidelines Committee, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.CrossRef
3.
Zurück zum Zitat Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43.CrossRef Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43.CrossRef
4.
Zurück zum Zitat Toh Y, Kitagawa Y, Kuwano H, et al. A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2016;13:173–81.CrossRef Toh Y, Kitagawa Y, Kuwano H, et al. A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2016;13:173–81.CrossRef
5.
Zurück zum Zitat Inomata M, Shiroshita H, Uchida H, et al. Current status of endoscopic surgery in Japan: the 14th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery. Asian J Endosc Surg. 2020;13:7–18.CrossRef Inomata M, Shiroshita H, Uchida H, et al. Current status of endoscopic surgery in Japan: the 14th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery. Asian J Endosc Surg. 2020;13:7–18.CrossRef
6.
Zurück zum Zitat Numasaki H, Teshima T, Okuda Y, Japanese Society for Radiation Oncology Database Committee, et al. Japanese structure survey of radiation oncology in 2013. J Radiat Res. 2020;61:799–816.CrossRef Numasaki H, Teshima T, Okuda Y, Japanese Society for Radiation Oncology Database Committee, et al. Japanese structure survey of radiation oncology in 2013. J Radiat Res. 2020;61:799–816.CrossRef
7.
Zurück zum Zitat Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2008. Esophagus. 2015;12:130–57.CrossRef Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2008. Esophagus. 2015;12:130–57.CrossRef
8.
Zurück zum Zitat Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1–24.CrossRef Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1–24.CrossRef
9.
Zurück zum Zitat Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef
10.
Zurück zum Zitat Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part ii and III. Esophagus. 2017;14:37–65.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part ii and III. Esophagus. 2017;14:37–65.CrossRef
12.
Zurück zum Zitat Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol. 2013;8:1558–62.CrossRef Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol. 2013;8:1558–62.CrossRef
13.
Zurück zum Zitat Yamashita K, Watanabe M, Mine S, et al. Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy. World J Surg. 2017;41:2337–44.CrossRef Yamashita K, Watanabe M, Mine S, et al. Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy. World J Surg. 2017;41:2337–44.CrossRef
14.
Zurück zum Zitat Steffen T, Dietrich D, Schnider A, Swiss Group for Clinical Cancer Research (SAKK), et al. Recurrence patterns and long-term results after induction chemotherapy, chemoradiotherapy, and curative surgery in patients with locally advanced esophageal cancer. Ann Surg. 2019;269:83–7.CrossRef Steffen T, Dietrich D, Schnider A, Swiss Group for Clinical Cancer Research (SAKK), et al. Recurrence patterns and long-term results after induction chemotherapy, chemoradiotherapy, and curative surgery in patients with locally advanced esophageal cancer. Ann Surg. 2019;269:83–7.CrossRef
15.
Zurück zum Zitat Xi M, Xu C, Liao Z, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;124:318–24.CrossRef Xi M, Xu C, Liao Z, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;124:318–24.CrossRef
16.
Zurück zum Zitat Schizas D, Lazaridis II, Moris D, et al. The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature. World J Surg Oncol. 2018;16:55.CrossRef Schizas D, Lazaridis II, Moris D, et al. The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature. World J Surg Oncol. 2018;16:55.CrossRef
17.
Zurück zum Zitat Schizas D, Mylonas KS, Kapsampelis P, et al. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interact Cardiovasc Thorac Surg. 2020;31:299–304.CrossRef Schizas D, Mylonas KS, Kapsampelis P, et al. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interact Cardiovasc Thorac Surg. 2020;31:299–304.CrossRef
18.
Zurück zum Zitat Kroese TE, Dijksterhuis WPM, van Rossum PSN, et al. Prognosis of interval distant metastases after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Thorac Surg. 2021;S0003–4975(21):00306–14. Kroese TE, Dijksterhuis WPM, van Rossum PSN, et al. Prognosis of interval distant metastases after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Thorac Surg. 2021;S0003–4975(21):00306–14.
19.
Zurück zum Zitat Seesing MFJ, van der Veen A, Brenkman HJF, Gastroesophageal Metastasectomy Group, et al. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus. 2019;32:034. Seesing MFJ, van der Veen A, Brenkman HJF, Gastroesophageal Metastasectomy Group, et al. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus. 2019;32:034.
20.
Zurück zum Zitat Matsubara T, Yamada K, Nakagawa A. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:4336–41.CrossRef Matsubara T, Yamada K, Nakagawa A. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:4336–41.CrossRef
21.
Zurück zum Zitat van der Schaaf M, Rutegård M, Lagergren P. The influence of surgical factors on persisting symptoms 3 years after esophageal cancer surgery: a population-based study in Sweden. Ann Surg Oncol. 2013;20:1639–45.CrossRef van der Schaaf M, Rutegård M, Lagergren P. The influence of surgical factors on persisting symptoms 3 years after esophageal cancer surgery: a population-based study in Sweden. Ann Surg Oncol. 2013;20:1639–45.CrossRef
22.
Zurück zum Zitat Schandl A, Johar A, Lagergren J, et al. Lymphadenectomy and health-related quality of life after oesophageal cancer surgery: a nationwide, population-based cohort study. BMJ Open. 2016;6:e012624.CrossRef Schandl A, Johar A, Lagergren J, et al. Lymphadenectomy and health-related quality of life after oesophageal cancer surgery: a nationwide, population-based cohort study. BMJ Open. 2016;6:e012624.CrossRef
23.
Zurück zum Zitat Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. Br J Surg. 2009;96:1308–14.CrossRef Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. Br J Surg. 2009;96:1308–14.CrossRef
24.
Zurück zum Zitat Schandl A, Lagergren J, Johar A, et al. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer. 2016;69:43–50.CrossRef Schandl A, Lagergren J, Johar A, et al. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer. 2016;69:43–50.CrossRef
25.
Zurück zum Zitat Lv Y, Zhang J, Qiao L. Quality of life in patients with esophageal cancer receiving definitive chemoradiotherapy or esophagectomy. Mol Clin Oncol. 2014;2:870–4.CrossRef Lv Y, Zhang J, Qiao L. Quality of life in patients with esophageal cancer receiving definitive chemoradiotherapy or esophagectomy. Mol Clin Oncol. 2014;2:870–4.CrossRef
26.
Zurück zum Zitat Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–14.CrossRef Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–14.CrossRef
27.
Zurück zum Zitat Ito H, Itasaka S, Sakanaka K, et al. Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res. 2017;58:106–13.CrossRef Ito H, Itasaka S, Sakanaka K, et al. Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res. 2017;58:106–13.CrossRef
28.
Zurück zum Zitat Wikman A, Ljung R, Johar A, et al. Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. J Clin Oncol. 2015;33:448–54.CrossRef Wikman A, Ljung R, Johar A, et al. Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. J Clin Oncol. 2015;33:448–54.CrossRef
29.
Zurück zum Zitat Mantoan S, Cavallin F, Pinto E, et al. Long-term quality of life after esophagectomy with gastric pull-up. J Surg Oncol. 2018;117:970–6.CrossRef Mantoan S, Cavallin F, Pinto E, et al. Long-term quality of life after esophagectomy with gastric pull-up. J Surg Oncol. 2018;117:970–6.CrossRef
Metadaten
Titel
Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan
verfasst von
Tomonori Nakanoko
Masaru Morita
Yuichiro Nakashima
Mitsuhiko Ota
Masahiko Ikebe
Manabu Yamamoto
Eisuke Booka
Hiroya Takeuchi
Yuko Kitagawa
Hisahiro Matsubara
Yuichiro Doki
Yasushi Toh
Publikationsdatum
12.08.2021
Verlag
Springer Singapore
Erschienen in
Esophagus / Ausgabe 1/2022
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-021-00869-3

Weitere Artikel der Ausgabe 1/2022

Esophagus 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.